Patents by Inventor Grant Young

Grant Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11973326
    Abstract: A power distribution box is disclosed. The power distribution box may include a housing including one or more panels. The one or more panels may define a cavity. The power distribution box may include one or more outlets coupled to one or more portions of the one or more panels of the housing. The power distribution box may include one or more output plugs configured to receive one or more power distribution whips. The one or more output plugs may be configured to couple to one or more portions of the one or more panels of the housing. The power distribution box may include one or more circuit breakers coupled to one or more portions of the one or more panels of the housing. The power distribution box may include at least one power whip coupled to an output plug of the one or more output plugs.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: April 30, 2024
    Assignee: VERTIV CORPORATION
    Inventors: James Brooks, Josef Feigl, Brad Wilson, Grant Young, Alexander Zink
  • Publication number: 20240124417
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: October 1, 2020
    Publication date: April 18, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kap-Sun YEUNG, Denis R. ST. LAURENT, Li-Qiang SUN, Zhiwei YIN, Katharine A. GRANT-YOUNG, Paul Michael SCOLA
  • Publication number: 20230414675
    Abstract: The present disclosure relates to an in vitro method for enhancing engraftment of isolated pancreatic cells comprising the step of contacting an isolated pancreatic cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general formula I:
    Type: Application
    Filed: September 7, 2023
    Publication date: December 28, 2023
    Inventors: Lachlan Grant Young, A.M. James Shapiro
  • Patent number: 11826387
    Abstract: The present disclosure relates to an in vitro method for enhancing engraftment of neurosensory precursor cell comprising the step of contacting an isolated neurosensory precursor cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate thereof:
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: November 28, 2023
    Assignee: Protokinetix Inc.
    Inventor: Lachlan Grant Young
  • Publication number: 20230338464
    Abstract: The present document describes methods of using a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general formula I for the treatment or prevention of dry eye disease in a subject in need thereof and/or for the treatment or prevention of a retinal degenerative disease, an ocular inflammation, or a combination thereof.
    Type: Application
    Filed: March 10, 2021
    Publication date: October 26, 2023
    Inventor: Lachlan Grant YOUNG
  • Publication number: 20230142705
    Abstract: The present document describes uses and methods of using a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general formula I for inhibition or prevention of immune rejection of an isolated graft contacted with said compound, prior to transplantation in a subject in need thereof.
    Type: Application
    Filed: January 22, 2021
    Publication date: May 11, 2023
    Inventor: Lachlan Grant YOUNG
  • Publication number: 20220200250
    Abstract: A power distribution box is disclosed. The power distribution box may include a housing including one or more panels. The one or more panels may define a cavity. The power distribution box may include one or more outlets coupled to one or more portions of the one or more panels of the housing. The power distribution box may include one or more output plugs configured to receive one or more power distribution whips. The one or more output plugs may be configured to couple to one or more portions of the one or more panels of the housing. The power distribution box may include one or more circuit breakers coupled to one or more portions of the one or more panels of the housing. The power distribution box may include at least one power whip coupled to an output plug of the one or more output plugs.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 23, 2022
    Inventors: James Brooks, Josef Feigl, Brad Wilson, Grant Young, Alexander Zink
  • Publication number: 20210389375
    Abstract: The present disclosure relates to a shared transfer switching system with built in relay testing ability, for transferring power received by a load from a preferred AC power source to an alternate AC power source, or transferring power being received by the load from the alternate AC power source to the preferred AC power source. The system selectively controls various ones of the relays used to apply power from either the preferred or alternate power sources to the load, such that the relays are switched from open to closed states at controlled times, while voltage measurements are made at select locations between the relays. The system can identify which specific ones of a plurality of relays associated with each of the preferred and alternate power sources has properly opened and closed, and thus verify that all of the relays needed to switch between the preferred and alternate power sources are operating properly.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 16, 2021
    Inventors: Scott COOPER, Kevin R. FERGUSON, Grant YOUNG
  • Publication number: 20210330712
    Abstract: The present disclosure relates to an in vitro method for enhancing engraftment of neurosensory precursor cell comprising the step of contacting an isolated neurosensory precursor cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate thereof:
    Type: Application
    Filed: July 7, 2021
    Publication date: October 28, 2021
    Inventor: Lachlan Grant Young
  • Patent number: 11096968
    Abstract: The present disclosure relates to an in vitro method for enhancing engraftment of neurosensory precursor cell comprising the step of contacting an isolated neurosensory precursor cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate thereof: (I).
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 24, 2021
    Assignee: Protokinetix Inc.
    Inventor: Lachlan Grant Young
  • Publication number: 20210023142
    Abstract: The present disclosure relates to an in vitro method for enhancing engraftment of isolated pancreatic cells comprising the step of contacting an isolated pancreatic cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general formula I:
    Type: Application
    Filed: September 30, 2020
    Publication date: January 28, 2021
    Inventors: Lachlan Grant Young, A.M. James Shapiro
  • Patent number: 10882844
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: January 5, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young, Li-Qiang Sun, David R. Langley, Denis R. St. Laurent, Paul M. Scola
  • Patent number: 10745382
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: August 18, 2020
    Assignee: bristol-myers squibb company
    Inventors: Kap-Sun Yeung, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
  • Patent number: 10590105
    Abstract: The present disclosure generally relates to compounds of formula (I), wherein R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: March 17, 2020
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, Zhaoxing Meng, Paul Michael Scola
  • Patent number: 10538555
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: January 21, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Kevin W. Gillman, Qian Zhao, Katharine A. Grant-Young, Paul Michael Scola, Lyndon A. M. Cornelius
  • Publication number: 20190352280
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 19, 2017
    Publication date: November 21, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kap-Sun YEUNG, Katharine A. GRANT-YOUNG, Li-Qiang SUN, David R. LANGLEY, Denis R. ST. LAURENT, Paul M. SCOLA
  • Publication number: 20190185450
    Abstract: The present disclosure generally relates to compounds of formula (I), wherein R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: July 5, 2017
    Publication date: June 20, 2019
    Inventors: Kap-Sun YEUNG, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, Zhaoxing Meng, Paul Michael Scola
  • Publication number: 20190046582
    Abstract: The present disclosure relates to an in vitro method for enhancing engraftment of neurosensory precursor cell comprising the step of contacting an isolated neurosensory precursor cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate thereof: (I).
    Type: Application
    Filed: January 27, 2017
    Publication date: February 14, 2019
    Inventor: Lachlan Grant Young
  • Patent number: 10144706
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: December 4, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, David R. Langley, Piyasena Hewawasam, Tao Wang, Zhongxing Zhang, Zhaoxing Meng, Li-Qiang Sun, Eric Mull, Paul Michael Scola
  • Patent number: 10143746
    Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: December 4, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Martin Patrick Allen, Eric P. Gillis, David R. Langley, Michael Matthew Miller, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Katharine A. Grant-Young, Nicholas A. Meanwell, Paul Michael Scola